BRPI0503817A - complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada - Google Patents

complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada

Info

Publication number
BRPI0503817A
BRPI0503817A BRPI0503817-0A BRPI0503817A BRPI0503817A BR PI0503817 A BRPI0503817 A BR PI0503817A BR PI0503817 A BRPI0503817 A BR PI0503817A BR PI0503817 A BRPI0503817 A BR PI0503817A
Authority
BR
Brazil
Prior art keywords
immunogenic complex
present
silica
encapsulated
antigen
Prior art date
Application number
BRPI0503817-0A
Other languages
English (en)
Inventor
Ogari De Castro Pacheco
Osvaldo Augusto Brazil Es Anna
Lucildes Pita Mercuri
Jivaldo Do Rosario Matos
Marcia Carvalho De Abr Fantini
Original Assignee
Cristalia Prod Quimicos Farm
Fundacao De Amparo A Pesquisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cristalia Prod Quimicos Farm, Fundacao De Amparo A Pesquisa filed Critical Cristalia Prod Quimicos Farm
Priority to BRPI0503817-0A priority Critical patent/BRPI0503817A/pt
Priority to US12/066,489 priority patent/US8642258B2/en
Priority to EP06775036.4A priority patent/EP1942934B1/en
Priority to JP2008530281A priority patent/JP5091863B2/ja
Priority to ES06775036T priority patent/ES2423892T3/es
Priority to PCT/BR2006/000182 priority patent/WO2007030901A1/en
Priority to CA2621373A priority patent/CA2621373C/en
Priority to CN2006800383996A priority patent/CN101287491B/zh
Priority to KR1020087007043A priority patent/KR101089400B1/ko
Publication of BRPI0503817A publication Critical patent/BRPI0503817A/pt
Priority to ZA200802277A priority patent/ZA200802277B/xx
Priority to HK09102975.6A priority patent/HK1124791A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

COMPLEXO IMUNOGêNICO FORMADO POR ANTìGENOS VACINAIS ENCAPSULADOS POR SìLICA MESOPOROSA NANOESTRUTURA A presente invenção refere-se a um produto dito "complexo imunogênico" que compreende um adjuvante caracterizado por partículas sólidas de sílica mesoporosa nanoestruturada altamente ordenada, preferentemente a sílica SBA-15, e antígenos vacinais de naturezas diversas encapsulados nos ditos adjuvantes. O complexo imunogênico da presente invenção permite a apresentação dos antígenos que o compõe aos linfócitos de maneira segura, gradual e prolongada que leva a uma memória imunológica mais eficiente, aumenta a imunogenicidade do antígeno e melhora a produção de anticorpos. Isto garante uma proteção imunológica eficiente com menores quantidades de antígenos e/ou menos repetições de doses vacinais. Alem disso as características do complexo imunogênico da presente invenção promovem efetiva indução de imunidade de maneira homogênea em indivíduos "bons e maus respondedores".
BRPI0503817-0A 2005-09-12 2005-09-12 complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada BRPI0503817A (pt)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BRPI0503817-0A BRPI0503817A (pt) 2005-09-12 2005-09-12 complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada
PCT/BR2006/000182 WO2007030901A1 (en) 2005-09-12 2006-09-12 Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
EP06775036.4A EP1942934B1 (en) 2005-09-12 2006-09-12 Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
JP2008530281A JP5091863B2 (ja) 2005-09-12 2006-09-12 ナノ構造のメソポーラスシリカに組み込まれたワクチン抗原からなる免疫原性複合体
ES06775036T ES2423892T3 (es) 2005-09-12 2006-09-12 Complejo inmun�geno formado por ant�genos de vacuna encapsulados con s�lice mesoporosa nanoestructurada
US12/066,489 US8642258B2 (en) 2005-09-12 2006-09-12 Immunogenical complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
CA2621373A CA2621373C (en) 2005-09-12 2006-09-12 Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
CN2006800383996A CN101287491B (zh) 2005-09-12 2006-09-12 由使用纳米结构的中孔二氧化硅包囊的疫苗抗原形成的免疫原性复合物
KR1020087007043A KR101089400B1 (ko) 2005-09-12 2006-09-12 나노구조의 메소다공성 실리카에 의해 캡슐화된 백신항원에 의해 형성된 면역원 복합체
ZA200802277A ZA200802277B (en) 2005-09-12 2008-03-10 Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
HK09102975.6A HK1124791A1 (en) 2005-09-12 2009-03-30 Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0503817-0A BRPI0503817A (pt) 2005-09-12 2005-09-12 complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada

Publications (1)

Publication Number Publication Date
BRPI0503817A true BRPI0503817A (pt) 2007-05-15

Family

ID=37864579

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0503817-0A BRPI0503817A (pt) 2005-09-12 2005-09-12 complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada

Country Status (11)

Country Link
US (1) US8642258B2 (pt)
EP (1) EP1942934B1 (pt)
JP (1) JP5091863B2 (pt)
KR (1) KR101089400B1 (pt)
CN (1) CN101287491B (pt)
BR (1) BRPI0503817A (pt)
CA (1) CA2621373C (pt)
ES (1) ES2423892T3 (pt)
HK (1) HK1124791A1 (pt)
WO (1) WO2007030901A1 (pt)
ZA (1) ZA200802277B (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102896A1 (pt) * 2016-12-05 2018-06-14 Universidade Estadual De Campinas - Unicamp Vacina para haemophilus aegypus e uso

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0503817A (pt) 2005-09-12 2007-05-15 Cristalia Prod Quimicos Farm complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada
EP1960009B1 (en) 2005-12-13 2011-11-23 The President and Fellows of Harvard College Scaffolds for cell transplantation
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
WO2009146456A1 (en) 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
DE102008033175A1 (de) * 2008-07-15 2010-01-21 Merck Patent Gmbh Siliciumdioxid-Nanopartikel und deren Verwendung zur Vakzinierung
JP2010083834A (ja) * 2008-10-01 2010-04-15 Naris Cosmetics Co Ltd アレルゲン不活性化剤、及びそれを含有する化粧料。
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
AU2010278702C1 (en) 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
EP2542230A4 (en) 2010-03-05 2013-08-28 Harvard College ENHANCEMENT OF SKELETAL MUSCLE STRAIN CELL GRAFT WITH DUAL DELIVERY OF VEGF AND IGF-1
EP2585053A4 (en) 2010-06-25 2014-02-26 Harvard College COMMON RELEASE OF STIMULATING AND HEMMING FACTORS FOR THE PRODUCTION OF TEMPORARY STABILIZED AND SPATULARLY LIMITED ZONES
KR102155383B1 (ko) 2010-10-06 2020-09-11 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 재료에 기초한 세포 치료를 위한 주사 가능한 기공 형성 하이드로겔
US9603894B2 (en) 2010-11-08 2017-03-28 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
WO2012148684A1 (en) 2011-04-27 2012-11-01 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
WO2012149358A1 (en) 2011-04-28 2012-11-01 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
AU2012261848B2 (en) 2011-06-03 2017-06-15 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
CN103012594B (zh) * 2011-09-22 2015-09-02 中国农业科学院兰州兽医研究所 一种运载猪圆环病毒抗原表位蛋白的纳米载体及应用
JP5999639B2 (ja) * 2011-11-25 2016-09-28 国立研究開発法人産業技術総合研究所 免疫刺激因子担持微粒子
PT2838515T (pt) * 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
PL2919903T3 (pl) 2012-11-14 2020-12-14 W.R. Grace & Co. - Conn. Kompozycje zawierające materiał biologicznie aktywny i nieuporządkowany tlenek nieorganiczny
US20160151482A1 (en) * 2013-04-02 2016-06-02 Stc. Unm Mesoporous alum nanoparticles as a universal platform for antigen adsorption, presentation, and delivery
CA2933910A1 (en) * 2013-12-19 2015-06-25 The University Of Queensland Method of synthesis of silica vesicles and use thereof
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
CN105267970A (zh) * 2015-01-08 2016-01-27 浙江大学 一种表面具有二氧化硅的热稳定疫苗及其制备方法
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
US11150242B2 (en) 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
JP6868862B2 (ja) * 2015-08-31 2021-05-12 国立研究開発法人産業技術総合研究所 メソポーラスシリカ粒子
CN105597094A (zh) * 2015-12-31 2016-05-25 河南农业大学 猪传染性胃肠炎病毒纳米硅佐剂灭活疫苗及其制备方法
WO2017120504A1 (en) 2016-01-08 2017-07-13 Durfee Paul N Osteotropic nanoparticles for prevention or treatment of bone metastases
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
JP2019522486A (ja) 2016-07-13 2019-08-15 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗原提示細胞模倣足場およびそれを作製および使用するための方法
GB2552704A (en) * 2016-08-04 2018-02-07 Univ Bath Biomolecule preservation
CN106727426A (zh) * 2016-12-08 2017-05-31 中国药科大学 一种用于口服蛋白免疫载体的制备方法
WO2018160865A1 (en) 2017-03-01 2018-09-07 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
CN114377120B (zh) * 2022-01-10 2023-09-22 大连理工大学 一种以病毒样颗粒为模板的二氧化硅疫苗递送系统的构建及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057296A (en) * 1990-12-10 1991-10-15 Mobil Oil Corp. Method for synthesizing mesoporous crystalline material
US5102643A (en) * 1990-01-25 1992-04-07 Mobil Oil Corp. Composition of synthetic porous crystalline material, its synthesis
AU7881000A (en) * 1999-08-16 2001-03-13 Henceforth Hibernia, Inc. Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them
US20020051794A1 (en) * 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
CN1193818C (zh) * 2002-03-13 2005-03-23 华东理工大学 一种二氧化硅磁性微球及其制备方法
US20040005352A1 (en) * 2002-04-16 2004-01-08 Lopez Gabriel P. Biologically functionalized porous microspheres
JP2004083501A (ja) * 2002-08-28 2004-03-18 Toyota Central Res & Dev Lab Inc 安定化抗体とこれを利用する免疫反応法及び免疫反応装置
JP2004155745A (ja) * 2002-11-08 2004-06-03 Kumamoto Technology & Industry Foundation ペプチドおよびその利用
US20040101822A1 (en) * 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
JP2004321010A (ja) * 2003-04-21 2004-11-18 Japan Science & Technology Agency 新規レンサ球菌タンパク質抗原
US20060018966A1 (en) * 2003-07-22 2006-01-26 Lin Victor S Antimicrobial mesoporous silica nanoparticles
US7563451B2 (en) * 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
JP4429105B2 (ja) * 2003-08-19 2010-03-10 キヤノン株式会社 有機物固定化構造体及びその製造方法、ペプチド及びｄｎａ
BRPI0503817A (pt) 2005-09-12 2007-05-15 Cristalia Prod Quimicos Farm complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102896A1 (pt) * 2016-12-05 2018-06-14 Universidade Estadual De Campinas - Unicamp Vacina para haemophilus aegypus e uso

Also Published As

Publication number Publication date
JP5091863B2 (ja) 2012-12-05
CN101287491B (zh) 2013-01-30
KR101089400B1 (ko) 2011-12-07
US20080286371A1 (en) 2008-11-20
WO2007030901A1 (en) 2007-03-22
US8642258B2 (en) 2014-02-04
CN101287491A (zh) 2008-10-15
KR20080047569A (ko) 2008-05-29
EP1942934A1 (en) 2008-07-16
CA2621373C (en) 2014-05-27
ZA200802277B (en) 2009-01-28
EP1942934B1 (en) 2013-05-01
HK1124791A1 (en) 2009-07-24
JP2009507859A (ja) 2009-02-26
ES2423892T3 (es) 2013-09-25
CA2621373A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
BRPI0503817A (pt) complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada
Fox et al. Working together: interactions between vaccine antigens and adjuvants
Azmi et al. Recent progress in adjuvant discovery for peptide-based subunit vaccines
EA200900024A1 (ru) Противогриппозная вакцина
Pfaar et al. Adjuvants for immunotherapy
EA200701786A1 (ru) Поливалентная противогриппозная иммуногенная композиция
Klimek et al. Clinical use of adjuvants in allergen-immunotherapy
Sanders et al. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines
ATE555808T1 (de) Impfstoffzusammensetzung mit einem synthetischen adjuvans
BRPI0206672B8 (pt) composição imunológica, vacina conjugada tetravalente e vacina meningocócica multivalente
JP6499446B2 (ja) 抗原特異的免疫モジュレーターとして選択担体、ビタミン、タンニンおよびフラボノイドの組み合わせを含有する医薬組成物
WO2009143457A3 (en) Vaccine composition containing synthetic adjuvant
EP2455101A3 (en) Influenza vaccine with oil-in-water emulsion adjuvant
EP2481422A3 (en) Multiplex vaccines
KR20130112790A (ko) 백신 조성물
WO2006097530A3 (en) Cat allergen fusion proteins and uses thereof
BRPI0515334A (pt) uso de um antìgeno de plasmodium
BR0314373A (pt) Produto imunogênico estável para a indução de anticorpos contra uma ou várias proteìnas antigênicas em um indivìduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
GB2442408A (en) Vaccine adjuvants
Pérez et al. Natural Neisseria derive proteoliposome and cochleate as potent vaccine adjuvants
BRPI0418332A (pt) adjuvantes vacinais, formulação vacinal, uso da formulação vacinal e esquema de imunização
Lea et al. Virosomal Hepatitis A Vaccine (Strain RG-SB) A Preliminary Review of its Immunogenicity, Protective Efficacy and Tolerability in At-Risk Populations
Gupta Role and application of adjuvants and delivery systems in vaccines
SG160386A1 (en) Novel composition
Menéndez et al. Purified capsular polysaccharide of Neisseria meningitidis serogroup A as immune potentiator for antibody production

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/07/2017, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2479 DE 10-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.